ArticleFrontiers in global women's health2025
Maternal substance use during pregnancy and associated factors in Adama, central Ethiopia.
Article in Frontiers in global women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Substance use, including tobacco, alcohol, khat, and illicit drugs, is a significant preventable contributor to the global burden of disease. Women are particularly vulnerable during their reproductive years, with substance use during pregnancy posing serious risks to maternal and fetal health. Therefore, this study aimed to assess of prevalence of substance use and determine associated risk factors among pregnant women in Adama, Central Ethiopia. Methods: A health facility-based cross-sectional study was conducted among 472 pregnant women. Participants were selected using a systematic sampling technique. Data were collected through an interviewer-administered structured questionnaire. Binary logistic regression was employed to model the association between substance use and explanatory variables. Adjusted odds ratios (AORs) with 95% confidence intervals (CIs) were used to estimate the strength of association. Statistical significance was determined at a Result: The overall prevalence of substance use during pregnancy was 22.0% (95% CI: 18.2-26.0). Unplanned pregnancy (AOR = 3.49, 95% CI: 1.23-9.89), pre-pregnancy substance use (AOR = 24.16, 95% CI: 11.49-40.82), husband/partner substance use (AOR = 4.51, 95% CI: 1.44-14.20), and ever heard about the side effects of substance use (AOR = 14.60, 95% CI: 5.31-17.65) were factors significantly associated with maternal substance use during pregnancy. Conclusion: Nearly one in four pregnant women reported using substances during pregnancy. Educational and counseling interventions during antenatal care should emphasize the risks of substance use on maternal health and fetal development, particularly targeting women with a history of substance use or unplanned pregnancies. Efforts should also involve partners and employ community-based strategies to raise awareness of these risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.